# FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

Source: https://onco.cc/trials/nct06858618/  
OnCo record `nct06858618` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Azacitidine in advanced solid tumours, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.

## Summary

FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms is a phase 2 interventional study registered as NCT06858618 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 47 participants enrolled, started 2023-08-16 and due to reach its primary completion in 2026-12-01. Interventions recorded: FCN-338 + Azacitidine and FCN-338 + erythromycin+ Ara-C.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06858618
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Safety & Tolerability, Antitumor Activity, and Pharmacokinetics of FCN-338 in Combination With Azacitidine or Chemotherapy in Patients With Myeloid Neoplasms
- Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Enrolled: 47

## Sources

- ClinicalTrials.gov NCT06858618: https://clinicaltrials.gov/study/NCT06858618

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/)
- companies: [Shanghai Fosun Pharmaceutical Industrial Development](https://onco.cc/companies/shanghai-fosun-pharmaceutical-industrial-development/)

---
JSON: https://onco.cc/api/v1/entities/nct06858618.json